AI Summary Resmetirom (Rezdiffra) is the first FDA-approved medication for MASH with moderate to advanced liver fibrosis (F2-F3), approved in March 2024.
Medically Reviewed.
Resmetirom (Rezdiffra) is an oral, liver-directed thyroid hormone receptor-beta (THR-β) agonist. It is the first FDA-approved medication specifically indicated for adults with metabolic dysfunction-associated steatohepatitis (MASH) who have moderate to advanced liver fibrosis (stage F2-F3) but not yet cirrhosis. Resmetirom acts directly in the liver to reduce fat accumulation, ease inflammation, and help improve fibrosis. It is not a weight-loss or diabetes medication, though it may also improve cholesterol levels. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Resmetirom's role in MASH management — how it works, who may be eligible, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Resmetirom fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT RESMETIROM TREATMENT
Resmetirom is a prescription medicine sold under the brand name Rezdiffra. It belongs to a class of medications called thyroid hormone receptor-beta (THR-β) agonists. It is the first FDA-approved treatment specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH), approved in March 2024.
Unlike GLP-1 medications such as Ozempic, Resmetirom is not a diabetes or weight-loss medication. Instead, it acts directly in the liver: activating THR-β receptors increases fat metabolism in liver cells, which helps reduce fat accumulation, ease inflammation, and improve or stabilize fibrosis (scarring) associated with MASH.
Resmetirom is approved for adults with MASH and moderate to advanced liver fibrosis (stage F2-F3) who do not yet have cirrhosis. It is typically used alongside dietary changes, physical activity, and regular monitoring by your healthcare provider, such as Liver Function Tests (LFTs) or imaging.
WHO RESMETIROM MAY BE SUITABLE FOR
Eligibility for Resmetirom depends on your diagnosis, disease stage, and individual health needs. Resmetirom is approved for adults with MASH confirmed by laboratory testing, imaging, or biopsy showing moderate to advanced liver fibrosis (stage F2-F3), but not cirrhosis. It may be considered when lifestyle changes alone have not adequately improved liver disease, or when a healthcare provider wants a treatment specifically targeted at liver fat and fibrosis.
Resmetirom is not typically recommended for people with cirrhosis, active uncontrolled liver disease such as autoimmune hepatitis, significant alcohol use, or untreated thyroid dysfunction, since these conditions need to be addressed or ruled out first. Your medical history, current health status, liver condition, and other medications all factor into whether Resmetirom is an appropriate option for you.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Resmetirom. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver condition and treatment goals.
ELIGIBILITY OVERVIEW
Resmetirom may be considered for adults with the following conditions, risk factors, or treatment goals:
Before recommending Resmetirom, healthcare providers evaluate several factors to determine whether it is an appropriate option, including:
HOW RESMETIROM CAN HELP YOUR LIVER
Resmetirom activates thyroid hormone receptor-beta (THR-β) receptors, which are concentrated in the liver. This activation increases fat metabolism inside liver cells, helping reduce the excess fat that builds up in MASH.
As liver fat decreases, inflammation tends to ease, and fibrosis (scarring) may improve or stabilize over time. Resmetirom may also help lower LDL ("bad") cholesterol and other harmful lipids, which supports broader metabolic health.
For patients with MASH and moderate to advanced fibrosis, these liver-directed effects can support treatment goals such as reduced liver fat, improved liver enzyme levels, and a lower risk of fibrosis progressing toward cirrhosis. Resmetirom is not used on its own — providers pair it with a calorie-appropriate diet, physical activity, and regular monitoring, such as Liver Function Tests (LFTs) and periodic imaging, to track response.
LIVER BENEFITS
Thyroid hormone receptor-beta (THR-β) receptors are concentrated in the liver. When resmetirom activates them, liver cells burn more fat, so less fat builds up inside them. In studies, a drop of 30% or more in liver fat on MRI-PDFF imaging was one sign of a favorable response. Providers read that result together with your other tests.
Less fat in liver cells helps reduce the inflammation that defines MASH (steatohepatitis). Your provider may follow liver enzymes such as ALT over time as one sign of this change. No single test tells the whole story, so results are always read in context.
Lower fat and less inflammation can help scarring (fibrosis) improve or stop progressing toward cirrhosis. Fibrosis changes slowly, so response is judged over months, not weeks. For people with advanced fibrosis, staying stable can still be a meaningful result, and your provider may recommend continuing treatment.
Resmetirom does not replace nutrition, exercise, or behavior changes. Liver care for MASLD and MASH includes lifestyle changes and control of related conditions such as diabetes and high cholesterol, whether or not you take resmetirom. Your care team uses these steps together.
Resmetirom works directly in the liver to reduce fat, ease inflammation, and support fibrosis improvement or stability in MASH. Your healthcare professional should start it and monitor it, with a full review of your response at about 12 months.
TREATMENT PROCESS
Resmetirom is supplied as an oral tablet. Take it exactly as prescribed by your healthcare provider, and check with your pharmacist if you have any questions about your specific tablet strength.
The recommended dose is based on body weight: 80 mg once daily for patients weighing less than 100 kg (220 lbs), and 100 mg once daily for patients weighing 100 kg (220 lbs) or more. Your healthcare provider determines the right dose for you.
Resmetirom is a once-daily oral tablet — it is not an injection or infusion. Take it with or without food, at the same time each day. Always use it exactly as your healthcare provider directs, and do not adjust your dose without medical guidance.
Resmetirom is intended as a long-term treatment for MASH with liver fibrosis. Continue treatment as prescribed, and do not stop taking it without first talking to your healthcare provider, since ongoing therapy may help slow disease progression.
Store resmetirom tablets at room temperature, away from moisture and heat.
Your healthcare provider will regularly monitor liver function tests, cholesterol levels, and treatment response. This may include imaging studies and other evaluations to track liver fat, inflammation, and fibrosis. Report any side effects or unusual symptoms to your healthcare provider.
BENEFITS AND SAFETY
Resmetirom (Rezdiffra) may support people with MASH and moderate to advanced liver fibrosis by acting directly in the liver to reduce fat accumulation and ease the inflammation that drives disease progression. Clinical studies have shown it may also help improve or stabilize fibrosis (scarring) and lower LDL ("bad") cholesterol and other harmful lipids. The extent of these benefits varies from person to person, depending on liver condition, overall metabolic health, and how the body responds to therapy. Resmetirom is not a stand-alone treatment — it works best as part of a broader, personalised care plan that combines the medication with a calorie-appropriate diet, regular physical activity, and ongoing monitoring like Liver Function Tests (LFTs) or imaging.
As with any medication, resmetirom may cause side effects, ranging from mild digestive symptoms to less common reactions such as itching or dizziness. Rarely, significant liver enzyme elevations or hepatotoxicity have occurred, so your healthcare provider will monitor your liver function throughout treatment and assess whether resmetirom remains a suitable option for you.
BENEFITS
In the MAESTRO-NASH trial, about 26–30% of people taking resmetirom had resolution of steatohepatitis without worsening fibrosis, compared with about 10% on placebo. Results differ from person to person.
In the same trial, about 24–26% of people on resmetirom had improved fibrosis without worsening steatohepatitis, compared with about 14% on placebo. This is a group result, not a promise for any one person.
Resmetirom lowered LDL cholesterol by about 13–16% in studies. It also reduced apolipoprotein B, triglycerides, and lipoprotein(a) compared with placebo. It is meant to be added to your current cholesterol care, not to replace it.
The FDA approved resmetirom in March 2024 as the first medication specifically for MASH. It gives eligible adults with moderate to advanced fibrosis (F2-F3) and no cirrhosis a treatment aimed at their liver disease.
Resmetirom is a once-daily tablet that you can take with or without food. It needs no injections or infusions. Your provider will review whether to continue, adjust, or stop treatment at about 12 months.
These effects are often more noticeable when starting treatment and may improve over a few weeks. Your healthcare provider will discuss the potential benefits and risks before treatment and provide ongoing support, including liver enzyme monitoring, to ensure safe use.
SUPPORTING YOUR RESULTS
Resmetirom should be used together with a healthy, calorie-appropriate diet, regular physical activity, weight management, and control of other metabolic risk factors. These lifestyle measures remain an essential part of MASH treatment alongside medication.
These habits can support how your liver responds to treatment and may help maximize improvements in liver fat, inflammation, and fibrosis over time.
Areas that may support treatment:
COMMON QUESTIONS
No, resmetirom is not a cure for MASH. It is a treatment that may help reduce liver fat, ease inflammation, and improve or stabilize fibrosis in adults with MASH and moderate to advanced liver fibrosis. Benefits vary by individual, and outcomes are not guaranteed. Resmetirom works alongside lifestyle changes and requires ongoing use and monitoring. Talk with your healthcare provider about realistic goals for your treatment plan.
Resmetirom is generally not recommended for people with cirrhosis, active uncontrolled liver disease such as autoimmune hepatitis, significant alcohol use, or untreated thyroid disorders, since these conditions need to be addressed first. It is approved for adults with MASH and fibrosis stage F2-F3, not F4 (cirrhosis). Your healthcare provider will review your liver condition, thyroid function, alcohol use, and medications before deciding if resmetirom is appropriate for you.
Response varies by person, and effects are typically assessed over time rather than immediately. In clinical practice, healthcare providers may use follow-up imaging or blood tests at around 12 months to help gauge changes in liver fat, liver enzymes, and fibrosis. Gastrointestinal side effects such as diarrhea and nausea often ease within the first few weeks. Your healthcare provider will monitor your progress and adjust your care plan as needed.
Yes, resmetirom can interact with certain medications, particularly some statins, since it affects how the body processes them. Combining resmetirom with gemfibrozil is not recommended, and doses of certain statins may need adjustment. Always tell your healthcare provider about every medication and supplement you take before starting resmetirom, so they can check for interactions and monitor your lipid levels and liver function throughout treatment.
The most common side effects are gastrointestinal symptoms such as diarrhea and nausea, along with itching (pruritus). These often appear early in treatment and tend to ease within several weeks. Resmetirom has also been associated with a higher chance of gallstones. Rare but serious liver injury has occurred, so your healthcare provider will monitor your liver enzymes regularly and discuss any new or worsening symptoms with you promptly.
Resmetirom is a thyroid hormone receptor-beta (THR-β) agonist that acts directly in the liver to reduce fat, inflammation, and fibrosis in MASH. GLP-1 medications like Ozempic primarily manage blood sugar and support weight loss, which may indirectly benefit the liver in metabolic dysfunction-associated steatotic liver disease (MASLD). Resmetirom is not a diabetes or weight-loss medication. Your healthcare provider can help determine which approach, or combination, fits your liver disease and metabolic health.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
